Physician profile
Caleb Burrows
NPI 1396123246
$2,605.32
in general payments reported to CMS, 2019-2025
13 companies · $561 in 2025
The $561 reported for 2025 was more than what a typical Otolaryngology/Facial Plastic Surgery provider received nationally (typical 2025 total: $305).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $801 · 2021: $143 · 2022: $101 · 2023: $553 · 2024: $447 · 2025: $561.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,561.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,561.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cochlear Americas | $438.29 | 2023-2025 | Baha, Cochlear Nucleus Ci632 Cochlear Implant With Slim Modiolar Electrode, Osia Osi300 Implant |
| Medtronic, INC. | $377.24 | 2022-2024 | Pteye Parathyroid Detection System |
| Stryker Corporation | $373.41 | 2019-2025 | Scopis Ent, Core, Shaver System |
| Regeneron Healthcare Solutions, INC. | $373.08 | 2019-2024 | Dupixent |
| Integra Lifesciences Corporation | $199.57 | 2019-2023 | Tenoglide |
| Medtronic USA, INC. | $175.03 | 2019 | |
| Intersect Ent, INC. | $142.59 | 2021 | |
| Mallinckrodt Enterprises LLC | $123.06 | 2019 | |
| Med-El Corporation | $116.50 | 2024 | Bci 602 Kit, Mi1250 Synchrony 2 Flexsoft |
| Glaxosmithkline, LLC. | $114.51 | 2025 | Nucala |
| Aerin Medical INC. | $113.31 | 2019 | |
| Smith+Nephew, INC. | $42.37 | 2019 | |
| Genzyme Corporation | $16.36 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Caleb Burrows listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.